What the research found
Lukac and colleagues reported a three-arm randomized trial in NEJM AI on November 26, 2025. Across 238 physicians at one academic health system, Nabla reduced electronic-record time spent in notes relative to usual practice; Microsoft DAX did not produce a statistically significant change in that primary measure. Secondary measures suggested possible improvements in physician experience. The finding supports evaluating individual implementations rather than assigning one effect to the entire ambient-scribe category. [1]
What the design can establish
The trial evaluated English-language encounters over a short period spanning late 2024 and early 2025. Its randomized comparison strengthens the documentation-time finding, but the secondary wellbeing findings require confirmation. Time recorded in a note is not a direct measure of appointment capacity, total clinical work, patient outcomes or financial return. Product versions and the surrounding workflow also bound generalizability. [1]
My operator interpretation
I would organize procurement around the bottleneck a clinical team wants to remove. A physician who completes documentation after work has a different problem from a clinic whose appointment availability is constrained by rooms or supporting staff. The same reduction in documentation burden could create personal time, improve attention during visits or enable additional activity. Management should choose the intended benefit explicitly before assigning it a dollar value.
That choice determines the pilot. I would define eligible encounters, record actual use and include the time spent checking, correcting and signing the output. Review should include encounters where the tool is declined, abandoned or unsuitable. Otherwise, a favorable result among enthusiastic users can conceal a difficult service to operate across the whole practice.
I would specify the financial mechanism before monetizing time. Reduced after-hours documentation can justify an investment in clinician experience without creating an additional billable encounter. Increased visit capacity requires a separate change in schedules, demand and supporting resources. Avoided staff expense requires an actual expenditure decision. Treating all three as interchangeable benefits overstates the return and makes a later renewal difficult to evaluate.
The model should price software, integration, training, review and support, then compare the result with other ways of relieving the same bottleneck. The opportunity cost may be additional staff, better templates or a different allocation of existing capacity. A technology can improve documentation and still lose that investment comparison. Procurement should show why this implementation is the preferred use of funds for this clinical team, rather than rely on a category-wide productivity promise.
The decision I would make
I would authorize expansion only for the specialties and workflows that demonstrate an acceptable combination of documentation quality, clinician burden, sustained use and total delivery cost. A renewal review should examine those measures together and revisit them after material product changes. This is a proposed purchasing discipline, not an outcome tested by the trial.
What this evidence cannot settle
The strategic recommendations are original interpretation. The cited trial does not establish clinical outcome improvement or a financial return from deployment.